Skip to content

Clinical Investigation to Assess the Feasibility of a New Diabetes Management Program

Clinical Investigation to Assess the Feasibility of a New Diabetes Management Program, the dALi System, for Pediatric Type 1 Diabetes (T1D) Subjects

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05793645
Acronym
ODIN
Enrollment
60
Registered
2023-03-31
Start date
2023-05-15
Completion date
2024-03-30
Last updated
2023-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Brief summary

The goal of this interventional study is to assess the adherence to a personalized care plan in patients (12-15 years) with Type 1 diabetes

Interventions

Algorithm that defines personalized care plan

Sponsors

Key2Compliance
CollaboratorINDUSTRY
NordicInfu Care AB
CollaboratorINDUSTRY
Air Liquide Santé International
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

* Male or female, 12-15 years of age. * T1D diagnosis minimum 8 months prior to the Screening/Initiation visit (Visit 0). * Equipped with Continuous Glucose Monitoring (CGM) System, intermittent or real-time, either alone or associated with an insulin pump system * Subject and health care provider must use a Remote diabetes management platform for the upload and follow-up of CGM, pump data or HCL data (e.g.: Glooko, Diasend). * Parent or guardian able and willing to give informed consent for the subject's participation in the investigation.

Exclusion criteria

* Initiation of use of HCL System during the last 2 months or during the investigation. * Use of Medtronic insulin pump. * Any disease or other medical condition, prior or concomitant medication /treatment /intervention, that may affect this clinical investigation or in other ways make the subject unsuitable for participation in this investigation, according to the judgement of the Principal Investigator (PI), or authorized designee. * Participation in any clinical investigation or study within the previous 30 days, that may affect the safety or performance of this investigation. * Mental incapacity precluding understanding or cooperation. * Subject not able to read and communicate in Swedish without an interpreter.

Design outcomes

Primary

MeasureTime frameDescription
Assessment of adherence15 weeksPercentage of patients adherent to the use of personalized care plan

Secondary

MeasureTime frameDescription
Change of MIND Youth-Questionnaire (MY-Q) score from the baseline phase to the post- intervention phase.15 weeksThe total score is calculated as the mean of 27 items. Higher score represent better QoL.
Assessment of empowerment using Gothenburg Young Persons Empowerment Scale- Diabetes (GYPES)15 weeksGYPES is a validated 15 items likert scale questionnaire measured at baseline phase and post intervention
Evaluation of the parents satisfaction with regards to the intervention15 weeksEvaluation of the parents satisfaction with the intervention using a likert scale at the end of the intervention
Evaluation of the children satisfaction with regards to the intervention15 weeksEvaluation of the children satisfaction with the intervention using a likert scale at the end of the intervention
Change in the estimated HbA1c from the baseline phase and post intervention15 weeksThe estimated HbA1c is based on average glucose measured continuously
Evolution of patient glycemic parameters from baseline to the end of intervention15 weeksGlycemic parameters measured are the Time in Range (TIR), the Time Above Range (TAR) and the Time Below Range (TBR). TIR, TAR and TBR refer to the percentage of CGM readings and time per day within, above and below the target glucose range
Description of Adverse eventsThrough study completion, an average of 15 weeksAll adverse events recorded by the investigator during the study period
Change of PedsQL Diabetes module score from the baseline phase to the post- intervention phase.15 weeksThe PedsQL Diabetes Module (PedsQL) is a validated 28-items likert scale questionnaire designed to assess diabetes-specific Helath Related Quality of Life children and adolescents. It contains questions related to diabetes management.

Countries

Sweden

Contacts

Primary ContactHenry TAUPIN
fralsi-ctpublication@airliquide.com+33619947113

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026